Amag Pharma a Magnificent Buy - Analyst Blog
AMAG Pharmaceuticals Inc. (AMAG) develops superparamagnetic iron oxide nanoparticles for use in pharmaceutical products. The company's focus is on developing IV iron replacement therapy for anemia in chronic kidney disease and an imaging agent to aid in diagnosis.
The company filed the NDA (new drug application) for its lead drug, Ferumoxytol, in December 2007, and we expect the FDA approval to come in late 2008 or early 2009. Clinical data in over 1,700 patients indicate an excellent safety profile for the drug, with lower incidents of heart problems.
Clinical results, and eventual approval, for additional indications should ensure strong growth in the coming years. We maintain our Buy rating on the shares of Amag with a target price of $55.
The above story is the opinion of the author only and it does not reflect
iStockAnalyst opinion. Further, the author is not personally advising you
regarding the suitability of the story for your investment needs. In no event
iStockAnalyst will be liable for any loss or damage including without
limitation, indirect or consequential loss or damage, or any loss or damage
whatsoever arising from or arising out of, or in connection with the use of this
information. Please consult your investment advisor before making any investment
decision.
